Bremelanotide (PT-141) is FDA-approved only for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and its labeling draws a fairly specific circle of people the published record says should not use it. The load-bearing limits are cardiovascular: a documented transient rise in blood pressure makes uncontrolled hypertension and known cardiovascular disease firm contraindications. One drug interaction, with oral naltrexone, is named in the label because slowed gastric emptying can drop that drug below its effective level.
Bremelanotide is FDA-approved only for premenopausal women with acquired, generalized HSDD, and is contraindicated in uncontrolled hypertension, known cardiovascular disease, and concurrent oral naltrexone use.
The cardiovascular signal is the defining limit on bremelanotide, and it traces to a transient pressor effect the trials measured directly. Each subcutaneous dose raises systolic pressure by an average of about 6 mmHg and diastolic by about 3, peaking within two to four hours and usually resolving inside twelve, with a small reflexive drop in heart rate. Trivial in a healthy person, that increment is the reason the label treats uncontrolled hypertension and established cardiovascular disease as firm grounds to withhold the drug.
A single subcutaneous dose of bremelanotide raises systolic blood pressure by roughly 6 mmHg and diastolic by roughly 3 mmHg, which is why FDA labeling contraindicates it in uncontrolled hypertension and known cardiovascular disease.
The absorption interaction is a direct consequence of melanocortin activity on gut motility, not a chemical incompatibility. Melanocortin signaling slows gastric emptying, so an orally administered drug reaches the small intestine, its main absorption site, later and at a blunted peak. In dedicated interaction studies this lowered the peak plasma concentration of a co-administered oral drug and delayed its time to peak, which matters most for drugs that need a reliable, timely level to work.
Bremelanotide slows gastric emptying, and interaction studies showed it lowers oral naltrexone exposure enough that the FDA label advises against relying on oral naltrexone in patients using the peptide.
Pregnancy and lactation both sit in the not-recommended column, driven more by absence of reassurance than by proof of harm. The pivotal trials excluded and screened against pregnancy, so no controlled human data characterize fetal risk, and animal reproduction studies raised developmental concerns at exposures relevant to human dosing. The on-demand dosing pattern, taken shortly before anticipated activity, creates a realistic window for exposure around the time of conception in a woman not using reliable contraception.
| Consideration | Pregnancy | Breastfeeding |
|---|---|---|
| Human data | Absent; trials screened against pregnancy | Passage into milk and infant effect uncharacterized |
| Animal data | Developmental concerns at human-relevant exposures | Not characterized |
| Labeled guidance | Advised against; discontinue if pregnancy occurs | Avoidance the cautious default while lactating |
Bremelanotide is not recommended in pregnancy or lactation because human safety data are absent and animal reproduction studies showed developmental concerns at human-relevant exposures.
The approved indication draws a narrow circle, and everyone outside it uses the drug without the trials that established its risk-benefit profile. The label covers premenopausal women with acquired, generalized HSDD, meaning a distressing loss of desire that developed after a period of normal function and is not tied to a specific situation or partner. Use in any other group is off-label and unsupported by the pivotal data.
The FDA-approved indication covers only premenopausal women with acquired, generalized HSDD, leaving men, postmenopausal women, and secondary low-desire cases as off-label, unvalidated use.
Organ impairment shifts bremelanotide from a straightforward prescription into a case-by-case judgment, because both clearance and the blood pressure response become less predictable. The peptide is removed through metabolism to inactive fragments plus renal and biliary routes, so kidneys and liver both share the work. On-demand dosing offers no steady-state maintenance dose to reduce, so there is no simple downward adjustment that reliably offsets impaired clearance.
In moderate to severe renal or hepatic impairment bremelanotide exposure and its pressor effect become less predictable, and because it is dosed on demand there is no maintenance-dose reduction to offset impaired clearance, so significant impairment favors avoidance.
The mitigations for the cardiovascular effect are structural, built into how and how often the drug is dosed rather than into ongoing lab monitoring. Confirmation of well-controlled blood pressure precedes the first dose, and the frequency caps carry most of the safeguard, since stacking doses is what turns a trivial pressure bump into a meaningful one. The pressor effect does not appear to accumulate with chronic intermittent use, but the ceilings hold regardless of tolerance.
Bremelanotide labeling caps dosing at one dose per 24 hours and eight doses per month, and pairs a pre-dose blood pressure confirmation with counseling to report headache, chest discomfort, or visual changes rather than redose.
Hypersensitivity is a lower-frequency but real consideration with any injectable peptide, and bremelanotide is no exception. The common local phenomena are injection-site reactions, redness, itching, and a small bruise or nodule, which are usually mild and self-limited. A genuine systemic reaction is a different matter and follows the standard allergy principle that a prior significant reaction contraindicates re-exposure.
A documented hypersensitivity to bremelanotide or any component of its formulation contraindicates re-exposure, and systemic signs such as diffuse rash, hives, facial swelling, or difficulty breathing call for stopping the drug and seeking evaluation.
Skin darkening is a direct pharmacologic signature of the drug's mechanism, not an incidental side effect. As a melanocortin receptor agonist, bremelanotide stimulates the same pathway that drives melanin production, so focal pigment increase is an expected consequence of activating it. The darkening appears more readily and more intensely in people with darker baseline skin and in those who dose more frequently, and it may not fully resolve after the drug is stopped.
Bremelanotide's melanocortin mechanism causes focal hyperpigmentation of the face, gums, and breasts that is more pronounced with darker skin and frequent dosing and may not fully reverse after discontinuation, making it a poor choice for patients prone to pigmentary changes.
A responsible prescribing workflow front-loads the very contraindications that define the drug, turning them into a short, deliberate screening sequence. Cardiovascular assessment and medication reconciliation do most of the work, since the cardiovascular limit and the oral naltrexone interaction are the two hard boundaries. Done well, this screening captures nearly every person who should avoid the drug before the first dose is dispensed.
A responsible bremelanotide screening sequence runs cardiovascular assessment, medication reconciliation flagging oral naltrexone, verification of the premenopausal acquired-and-generalized indication, and a pregnancy and contraception discussion before the first dose is dispensed.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
